chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 32.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Feeling abnormal, Respiratory rate decreased, Tremor
Clinical narrative: Intense sensation of trembling like I have low blood sugar; Breathing feels slowed; Intense fatigue; Everything is slowed.; This is a spontaneous report from a contactable consumer, the patient. A 32-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Unknown) via an unspecified route of administration in the right arm on 08Mar2021 at 15:15 (at the age of 32-years-old) as a single dose for COVID-19 immunisation. Medical history included irritable bowel syndrome (IBS), anxiety, bipolar disorder and temporomandibular joint disorder (TMJ disorder). The patient had known allergies to lavender and sulfa drugs. Concomitant medications included diazepam (MANUFACTURER UNKNOWN), fish oil (MANUFACTURER UNKNOWN), curcuma longa rhizome (TURMERIC) and unspecified women's multivitamin; all taken for unknown indications from an unknown date and unknown if ongoing. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 08Mar2021 at 16:45, the patient experienced intense fatigue, intense sensation of trembling like the patient had low blood sugar, breathing felt slowed and everything was slowed. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events intense sensation of trembling like the patient had low blood sugar, breathing felt slowed, everything was slowed and intense fatigue were not resolved at the time of this report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Gastrooesophageal reflux disease
Clinical narrative: Coinciding with vaccination timing, severe acid reflux was triggered; This is a spontaneous report from a contactable consumer, the patient. A 50-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6198) via an unspecified route of administration in the right arm on 24Feb2021 at 15:15 (at the age of 50-years-old) as a single dose for COVID-19 immunisation. Medical history included no evidence of disease (NED) for ovarian cancer and allergies to nuts and kiwi. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medication included vitamin D (MANUFACTURER UNKNOWN) for unknown indication from an unknown date and unknown if ongoing. On 25Feb2021, coinciding with vaccination timing, severe acid reflux was triggered in the patient and it was unclear that vaccine was the cause but primary care physician indicated to report this in case others experienced the same. The reflux was still ongoing 1.5 weeks post the first dose of vaccine (at the time of this report). The event resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of the event which included treatment with proton pump inhibitors (PPI's) awaiting issue resolution. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event severe acid reflux triggered was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 56.0
Sex: M
Vaccine: COVID19
Symptoms: Diarrhoea, Headache, Nausea, Vomiting
Clinical narrative: Vomiting; Diarrhea; Nausea; Headache (within 24 hours of shot).; This is a spontaneous report from a contactable consumer, the patient. A 56-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6205) via an unspecified route of administration in the left arm on 02Mar2021 at 12:30 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. Medical history included ulcerative colitis and seasonal allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included mesalazine (LIALDA), loratadine (CLARITIN), phleum pratense (GRASSTEK) and mutivitamins; all for unknown indication from an unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 06Mar2021, the patient experienced nausea and headache (within 24 hours of shot). nausea/vomiting/diarrhea (within 5 days of shot).The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events nausea, headache, vomiting and diarrhea was recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Dysgeusia, Paraesthesia oral
Clinical narrative: Tasted something weird; tongue started tingling all around the edges / tongue or roof of mouth has been tingling on and off; This is a spontaneous report from a contactable consumer, the patient. A 45-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6206) via an unspecified route of administration in the arm left on 05Mar2021 at 14:00 (at the age of 45-year-old) as a single dose for COVID-19 immunisation. Medical history included hashimoto's disease, addison's disease (primary adrenal failure), type 1 diabetes mellitus and allergy towards anti-nausea drugs. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included insulin lispro (HUMALOG), levothyroxine sodium (SYNTHROID), prednisone (MANUFACTURER UNKNOWN), iron (MANUFACTURER UNKNOWN), fludrocort (MANUFACTURER UNKNOWN) and extmbe (MANUFACTURER UNKNOWN) all from an unknown date and unknown if ongoing for an unknown indication. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 05Mar2021 at 14:40, 40 minutes after the vaccination, the patient had tasted something weird in the back of her throat and immediately after that the patient's tongue started tingling all around the edge. It was reported that since the injections, the patient's tongue or roof of mouth had been tingling on and off. The events did not result in doctor or other healthcare professional office/clinic visits, and the emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events tasted something weird and tongue started tingling all around the edges was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 35.0
Sex: M
Vaccine: COVID19
Symptoms: Fatigue
Clinical narrative: Moderate fatigue - required rest all day; This is a spontaneous report from a non-contactable healthcare professional, the patient.  A 35-year-old male patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6199) via an unspecified route of administration on 07Mar2021 at 19:00 (at the age of 35-years-old) as a single dose for COVID-19 immunisation. Medical history included chronic bronchitis. The patient had no known allergies to food, medications or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. On 07Mar2021, the patient experienced moderate fatigue. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were taken as a result of the event fatigue and included rest all the day. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event moderate fatigue was not recovered at the time of this report.  No follow-up attempts are possible. No further information is expected.
Age: 28.0
Sex: M
Vaccine: COVID19
Symptoms: Motor dysfunction, Muscle spasms
Clinical narrative: Did not have full control of ''my'' right hand. It has been three days now and ''I'' still have lost partial control of ''my'' hand./ almost no control in ''my'' fingers especially ''my'' pinky.; Would almost describe it as a muscle spasm or a cramp; This is a spontaneous report from a contactable consumer, the patient. A 28-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN5318) via an unspecified route of administration in the right arm on 05Mar2021 at 16:00 (at the age of 28-years-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient had no no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient did not take any concomitant medications. On 06Mar2021 at 12:00, the patient woke up Saturday morning, the day after getting the first vaccine shot and did not have full control of his right hand. It had been three days at the time of this report and still had lost partial control of hand, almost described it as a muscle spasm or a cramp. Whenever opened the hand could see that physically the hand was not right, it was almost as if there was no muscle on the side of the hand. The patient could make a fist but could not open hand and make fingers touch each other. The patient almost not had control in fingers especially his pinky. The patient was worried and needed to be contacted as soon as possible. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. No therapeutic measures were taken as a result of the reported events. The clinical outcome of the events did not have full control of his right hand, it had been three days and still had lost partial control of his hand and would almost describe it as a muscle spasm or a cramp was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Tinnitus
Clinical narrative: Tinnitus; This is a spontaneous report from a contactable consumer, the patient. A 64-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6206) via an unspecified route of administration in the left arm on 08Mar2021 at 12:00 (at the age of 64-years-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient had no known allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19.  The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included escitalopram oxalate (LEXAPRO) for an unknown indication from an unknown date and unknown if ongoing. On 08Mar2021 at 12:30, the patient experienced tinnitus. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event.  Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event tinnitus was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Sex: M
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: Upper arm where the shot was given was sore; This is a spontaneous report from a non-contactable consumer. A male patient of an unspecified age received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 04Mar2021 as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. It was unknown if prior to the vaccination, the patient was diagnosed with COVID-19. On 04Mar2021, the patient experienced that the upper arm where the shot was given was sore for about 2 to 3 days. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. It was unknown if therapeutic measures were taken as a result of the event. It was unknown if since the vaccination, the patient had been tested for COVID-19. The clinical outcome of the event sore upper arm where the shot was given was recovered on an unspecified date in Mar2021.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 47.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site erythema, Vaccination site warmth
Clinical narrative: red patch on my upper leftarm that has developed in the days since the shot was given. It's about 2 inches wide and feels warm to the touch. The red patch is located where I received my injection.; red patch on my upper leftarm that has developed in the days since the shot was given. It's about 2 inches wide and feels warm to the touch. The red patch is located where I received my injection.; This is a spontaneous report from a contactable consumer, the patient. A 47-year-old non-pregnant female patient received unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 06Mar2021 at 09:30 (at the age of 47-year-old) as a single dose for COVID-19 immunisation. Medical history included depression, asthma and irritable bowel syndrome. The patient had no allergies to food, drug or other product. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination.Concomitant medications included fluoxetine (MANUFACTURER UNKNOWN), omeprazole (MANUFACTURER UNKNOWN) and oral contraceptive nos (MANUFACTURER UNKNOWN); all for unknown indication, from an unknown date and unknown if ongoing.  On 08Mar2021 at 12:00, the patient experienced red patch on her upper left arm that was developed in the days since the shot was given. It was about 2 inches wide and felt warm to the touch. The red patch was located where the patient received injection. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of events. Since the vaccination, the patient had not been tested for COVID-19.  The clinical outcome of the event red patch on her upper left arm that was developed in the days since the shot was given, it was about 2 inches wide and felt warm to the touch and the red patch was located where the patient received injection was not recovered at the time of this report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 53.0
Sex: M
Vaccine: COVID19
Symptoms: Hypoaesthesia, Pain
Clinical narrative: Intense throbbing pain on the back of my neck below the cerebellum; Fingers numbness on both hands; This is a spontaneous report from a contactable consumer, the patient. A 53-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EM6206) via an unspecified route of administration in the left arm on 07Mar2021 at 09:45 (at the age of 53-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient previously received sulfamethoxazole/trimethoprim (MANUFACTURER UNKNOWN) and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient had not received any other medication with in two weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 08Mar2021 at 10:00, the patient experienced intense throbbing pain on the back of her neck below the cerebellum and fingers numbness on both hands. The events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not  been tested for COVID-19. The clinical outcome of the events intense throbbing pain on the back of her neck below the cerebellum and fingers numbness on both hands was resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Pain in extremity
Clinical narrative: Very sore right arm; Minor fatigue; This is a spontaneous report from a contactable consumer, the patient. A 65-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6198) via an unspecified route of administration in the right arm on 05Mar2021 at 13:00 (at the age of 65-years-old) as a single dose for COVID-19 immunisation. Medical history included sulfa allergy (sulfonamide allergy). Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient received other medicines (unspecified) within two weeks prior to the COVID-19 vaccine. On 05Mar2021 at 18:00, the patient experienced very sore right arm and minor fatigue. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event very sore right arm and minor fatigue was recovered on an unknown date in Mar2021.   No follow-up attempts are needed. No further information is expected.
Age: 67.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Myalgia
Clinical narrative: Extreme fatigue; Muscle pain; This is a spontaneous report from a contactable consumer, the patient. A 67-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6198) via an unspecified route of administration in the left arm on 01Mar2021 at 13:45 (at the age of 67-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient previously received codeine (MANUFACTURER UNKNOWN) for an unknown indication on an unknown date and experienced drug allergy. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. Concomitant medications included multivitamin (MANUFACTURER UNKNOWN), cholecalciferol (VITAMIN D3), ascorbic acid (VITAMIN C) and sertraline (MANUFACTURER UNKNOWN); all for an unknown indication from an unknown date and unknown if ongoing. On 07Mar2021, on 6th day after the first dose of vaccination, the patient experienced extreme fatigue and muscle pain that lasted for 24 hours. The adverse events did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care.  No therapeutic measures were taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events extreme fatigue and muscle pain were recovered on 08Mar2021 after the duration of 24 hours.   No follow-up attempts are needed. No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Dysgeusia
Clinical narrative: Strong metallic taste in mouth; This is a spontaneous report from a contactable consumer, the patient. A 37-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6205) via an unspecified route of administration in the left arm on 07Mar2021 at 13:15 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient had no allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. Concomitant medications included ergocalciferol (VITAMIN D2) and glucosamine (MANUFACTURER UNKNOWN) both for an unknown indication, from unknown date and unknown if ongoing. On 07Mar2021 at 13:15, approximately 5 minutes after the injection the patient experienced a strong metallic taste in mouth and it went away approximately 30 minutes after that. No therapeutic measures were taken as a result of the event. The adverse event did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event strong metallic taste in mouth was recovered on 07Mar2021.   No follow-up attempts are needed. No further information is expected.
Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: Blood test, White blood cell count increased
Clinical narrative: High white blood count; This is a spontaneous report from a contactable consumer, the patient. A 65-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 19Feb2021 at 07:30 (at the age of 65-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported. The patient previously had naproxen sodium (ALEVE) and experienced drug allergy. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 22Feb2021, 3 days after the vaccination, the patient had a high white blood count. On the same day, the patient underwent a blood test and the result was a high white blood count. Therapeutic measures were not taken as a result of the event. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and the emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event high white blood count was unknown at the time of this report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 37.0
Sex: M
Vaccine: COVID19
Symptoms: Lymph node pain, Lymphadenopathy
Clinical narrative: Swollen lymph node in left armpit.; Tender lymph node in left armpit.; This is a spontaneous report from a contactable consumer, the patient. A 37-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6199) via an unspecified route of administration in the left arm on 07Mar2021 at 14:00 (at the age of 37-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient had no known allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included vitamins nos (DAILY MULTIVITAMIN) for an unknown indication from an unknown date and unknown if ongoing. On 08Mar2021, the patient experienced swollen/ tender lymph node in left armpit. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event swollen/ tender lymph node in left armpit was unknown at the time of this report.    No follow-up attempts are needed. No further information is expected.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Muscle spasms
Clinical narrative: Muscle spasms in left cheek; This is a spontaneous report from a contactable consumer. A 60-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6205) via an unspecified route of administration in the left arm on 06Mar2021 at 16:15 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. Medical history included iodine allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any medication within 2 weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL9267) via an unspecified route of administration in the left arm on 13Feb2021 at 16:00 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. On 07Mar2021 at 09:00, the next day following the vaccine, the patient experienced muscle spasms in her left cheek for approximately 12 hours. The event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event muscle spasms in left cheek was recovered on 07Mar2021.   No follow-up attempts are needed. No further information is expected.
Age: 35.0
Sex: M
Vaccine: COVID19
Symptoms: Pain in extremity
Clinical narrative: Sore arm; This is a spontaneous report from a contactable consumer, the patient. A 35-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6204) via an unspecified route of administration in the right arm on 08Mar2021 at 17:30 (at the age of 35-years-old) as a single dose for COVID-19 immunisation. Medical history included human immunodeficiency virus syndrome (HIV). The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included paracetamol (ACETAMINOPHEN), emtricitabine/tenofovir alafenamide fumarate/bictegravir sodium (BIKTARVY), bupropion (MANUFACTURER UNKNOWN) and ibuprofen (MANUFACTURER UNKNOWN); all started from unknown dates for unspecified indications and were unknown if ongoing. On 08Mar2021 at 21:30, the patient experienced sore arm. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the reported event. The clinical outcome of the event sore arm was unknown at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 34.0
Sex: M
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: Mild soreness at injection site; This is a spontaneous report from a non-contactable consumer, the patient. A 34-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL3247) via an unspecified route of administration in the left arm on 02Mar2021 at 09:00 (at the age of 34-years-old) as a single dose for COVID-19 immunisation. Medical history included penicillin allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included famotidine (PEPCID), calcium carbonate (TUMS) and clindamycin phosphate (MANUFACTURER UNKNOWN) topical lotion; all for unknown indications, from unknown dates and unknown if ongoing. On 02Mar2021, the patient experienced mild soreness at injection site. The event did not result in doctor or other healthcare professional office/clinic, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event mild soreness at injection site was recovering at the time of this report.   No follow-up attempts are possible. No further information is expected.
Age: 19.0
Sex: F
Vaccine: COVID19
Symptoms: Diarrhoea, Pain in extremity
Clinical narrative: Diarrhea; Sore arm; This is a spontaneous report from a contactable consumer, the patient. A 19-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 02Mar2021 (at the age of 19-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medication were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. On an unknown date in Mar2021, the patient experienced diarrhea and sore arm. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events diarrhea and sore arm was unknown at the time of this report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Body temperature, Headache, Nausea, Pyrexia
Clinical narrative: Next day in the morning my temperature was 99 degrees. at 1 PM the temperature rose to 100.1 degrees; I also have a headache, nausea, and weakness; I also have a headache, nausea, and weakness; I also have a headache, nausea, and weakness; This is a spontaneous report from a contactable consumer, the patient. A 69-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6203) via an unspecified route of administration in the left arm on 02Mar2021 (at the age of 69-years-old) as a single dose for COVID-19 immunisation. The patient had no other relevant medical history and no known allergies to medications, food, or other products. The patient did not receive any concomitant medication within two weeks of vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EM9809) via an unspecified route of administration in the left arm on 09Feb2021 at 09:00 as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. After getting second dose on 02Mar2021, next day in the morning on 03Mar2021 at 10:00, the patients temperature was 99 degrees (units unspecified), at 13:00 the temperature rose to 100.1 degrees (units unspecified). On 03Mar2021 at 10:00 the patient also had a headache, nausea, and weakness. Therapeutic measures were not taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events next day in the morning temperature was 99 degrees (units unspecified), at 13:00 the temperature rose to 100.1 degrees (units unspecified); also had a headache, nausea, and weakness was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 84.0
Sex: M
Vaccine: COVID19
Symptoms: Dizziness
Clinical narrative: Dizzy; This is a spontaneous report from a contactable consumer. An 84-year-old male patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Unknown) via an unspecified route of administration on 03Mar2021 at 14:30 (at the age of 84-years-old) as a single dose for COVID-19 immunisation. Medical history included chronic obstructive pulmonary disorder (COPD), arthritis and known allergies to bees. It was unknown if the patient had any other medications within two weeks prior to the vaccination. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 03Mar2021, the patient reported that he was still dizzy about 45 minutes after vaccination. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event dizzy was resolved on 03Mar2021 at 15:15.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 30.0
Sex: F
Vaccine: COVID19
Symptoms: Dysgeusia
Clinical narrative: Sour taste in mouth; This is a spontaneous report from a non-contactable consumer, the patient. A 30-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on the right arm on 28Feb2021 at 14:00 (at the age of 30-years-old) as a single dose for COVID-19 immunisation. Medical history included gastrointestinal issues (GI) and irritable bowel syndrome (IBS). The patient had no known allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included magnesium (MANUFACTURER UNKNOWN) for an unknown indication from an unknown date and unknown if ongoing. On 01Mar2021, the patient experienced sour taste in mouth. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event sour taste in mouth was not recovered at the time of this report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Lymphadenopathy
Clinical narrative: Enlarged lymph node in armpit of arm shot was given; This is a spontaneous report from a non-contactable consumer, the patient. A 45-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date (at the age of 45-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported.  On 01Mar2021, the patient experienced enlarged lymph node in armpit of arm shot was given. Therapeutic measures were not taken as a result of the events. The adverse event did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event enlarged lymph node in armpit of arm shot was given was not resolved at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained. No further information is expected.
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: Arm sore at injection site; This is a spontaneous report from a non-contactable consumer, the patient. A 35-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN5318) via an unspecified route of administration in the left arm on 03Mar2021 at 08:00 (at the age of 35-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included vitamin D nos (MANUFACTURER UNKNOWN) and iron supplement (MANUFACTURER UNKNOWN), both taken for an unspecified indication from an unknown date and unknown if ongoing. On 03Mar2021 at 14:00, the patient experienced arm sore at injection site. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event arm sore at injection site was recovering at the time of this report.   No follow-up attempts are possible. No further information is expected.
Age: 22.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Dizziness, Fatigue
Clinical narrative: Dizziness; Fatigue; Weaknezz; This is a spontaneous report from a non-contactable consumer, the patient. A 22-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date in 2021 (at the age of 22-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications were not reported. On 03Mar2021, the patient experienced dizziness, fatigue and weakness. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events dizziness, fatigue and weakness were unknown at the time of this report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: Lymph node pain, Lymphadenopathy, Pain, Pain in extremity, Vertigo
Clinical narrative: Pain of lymph nodes in left armpit and left side collarbone; Swelling of lymph nodes in left armpit and left side collarbone; Vertigo; Severe arm pain; Full body soreness; This is a spontaneous report from a non-contactable consumer, the patient. A 36-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6202) via an unspecified route of administration in the left arm on 27Feb2021 at 12:00 (at the age of 36-years-old) as a single dose for COVID-19 immunisation. Medical history included known allergies to peanuts, walnuts, cats, hazelnut, timothy grass, baja grass. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included loratadine (CLARITIN), hydroxyzine (MANUFACTURER UNKNOWN), caffine/paracetamol (EXCEDRIN), Iron (MANUFACTURER UNKNOWN) and colecalciferol (VITAMIN D3); all for an unknown indication from an unknown date start date and unknown if ongoing. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EM9810) via an unspecified route of administration on 04Feb2021 at 17:30 (at the age of 36-years-old) as a single dose for COVID-19 immunisation. On 28Feb2021, after 3 days of vaccination, the patient experienced pain and swelling of lymph nodes in left armpit and left side collarbone starting 3 days after injection. Vertigo and severe arm pain the night of the injection. Full body soreness for three days after, preceding swelling and painful lymph nodes in armpit and collarbone. The events did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. No therapeutic measures were taken as a result of the reported events. The clinical outcome of the events pain of lymph nodes in left armpit and left side collarbone, swelling of lymph nodes in left armpit and left side collarbone were recovering while vertigo, severe arm pain and full body soreness were not recovered at the time of reporting.   No follow-up attempts are possible. No further information is expected.
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Myalgia
Clinical narrative: Moderate-strong left arm muscle pain; Minor joint aches/pain; This is a spontaneous report from a contactable consumer, the patient. A 55-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: E23247) via an unspecified route of administration in the left arm on 01Mar2021 at 10:00 (at the age of 55-years-old) as a single dose for COVID-19 immunisation. Medical history included migraines. The patient had no known allergies to medications, food or to other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any concomitant medications. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 01Mar2021, the patient experienced moderate-strong left arm muscle pain and minor joint aches/pain. The events did not result in doctor or other health care professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events moderate-strong left arm muscle pain and minor joint aches/pain was recovered on an unspecified date in Mar2021.   No follow-up attempts are needed. No further information is expected.
Age: 68.0
Sex: M
Vaccine: COVID19
Symptoms: Blood pressure abnormal, Blood pressure measurement, Blood test, Renal function test
Clinical narrative: It effected "my" blood pressure; This is a spontaneous report from a contactable consumer, the patient. A 68-year-old male patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 01Mar2021 at 10:30 (at the age of 68-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Concomitant medications were not reported. On 01Mar2021 at 11:30, the patient's blood pressure was effected and kidney lab reports which were taken approximately 2 hours after vaccination. Blood pressure returned to normal a day later and was awaiting kidney lab/blood test in 3 weeks. It was also reported that this was not a life endangering or serious effect, but might need to be identified. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. On 01Mar2021, the patient underwent blood pressure test, kidney function test/blood test and the results were not provided and blood pressure returned to normal a day later on 02Mar2021. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event blood pressure was effected was resolved on 02Mar2021.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 67.0
Sex: M
Vaccine: COVID19
Symptoms: Migraine with aura
Clinical narrative: Seemed to trigger a migraine with aura.; This is a spontaneous report from a non-contactable consumer, the patient. A 67-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 05Mar2021 at 08:00 (at the age of 67-years-old) as a single dose for COVID-19 immunisation. Medical history included cancer and migraine. The patient had no known allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. Concomitant medications included valproate semisodium (DEPAKOTE) and propranolol (PROPANOLOL) for unknown indication from an unknown date and unknown if ongoing. On 08Mar2021 at 14:00, the patient experienced migraine with aura. The patient was migraine sufferer but this seemed to trigger a migraine with aura which he never had before. Therapeutic measures were taken as a result of the reported events which included treatment with rimegepant (NURTEC). Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of event migraine with aura was recovered on 08Mar2021.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Sex: F
Vaccine: COVID19
Symptoms: Eye irritation, Visual impairment
Clinical narrative: Vision issues; Burning of eyes; This is a spontaneous report from a non-contactable consumer, the patient. An adult non-pregnant female patient of an unspecified age received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date as a single dose for COVID-19 immunisation. Medical history was not reported. The patient did not have known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications were not reported. On an unknown date the patient experienced vision issues and burning of eyes. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event vision issues and burning of eyes was resolving at the time of this report.    No follow-up attempts are possible; information about lot number cannot be obtained. No further information is expected.